Providers

Latest News

AJMC
Longitudinal, Relationship-Based Case Management: A Prospective Cohort Trial

May 6th 2025

A longitudinal, relationship-based case management approach significantly reduced health care costs and improved quality of life for Medicaid enrollees with complex needs over 1 year.

Andrew Evens, DO
Expanding Resources, Clinical Knowledge to Enhance AYA NHL Care: Andrew Evens, DO

May 2nd 2025

While both are anti-CD20 antibodies, obinutuzumab is a glycoengineered type II CD20 antibody, and rituximab is a type I CD20 antibody, meaning a different mode of binding to CD20 antigen. | Image credit: Eleni - stock.adobe.com
Long-Term Data Show Favorable Survival Outcomes With G-Clb in Treatment-Naive CLL

May 1st 2025

Liver cancer - Sebastian Kaulitzki - stock.adobe.com.jpg
Elevated HLA-G Seen in HCC Driven by Viral Infections, Fatty Liver

May 1st 2025

The results offer some of the first glimpses into real-world findings of the JAK inhibitor momelotinib, which was approved in 2023. | Image credit: mdaros - stock.adobe.com
Real-World Findings Confirm Clinical Data on Momelotinib in MF With Anemia

May 1st 2025

More News

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo